Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Epidemiology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.2046/fullpdf
Reference19 articles.
1. TNF-alpha in promotion and progression of cancer;Balkwill;Cancer Metastasis Rev,2006
2. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility;van Horssen;Oncologist,2006
3. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials;Bongartz;Jama,2006
4. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data meta-analysis of Randomized Controlled Trials;Bongartz;Ann Rheum Dis,2009
5. The safety of anti-Tumor Necrosis Factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events;Leombruno;Ann Rheum Dis,2009
Cited by 249 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study;Seminars in Arthritis and Rheumatism;2024-02
2. Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions;Clinical and Experimental Gastroenterology;2023-12
3. Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies;Annals of the Rheumatic Diseases;2023-11-06
4. The selection of the initial drug in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2023-09-27
5. Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers—A Narrative Review of Potential Physiopathological and Biological Mechanisms;Cells;2023-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3